

### **ERN-Skin**

Prof. C. Bodemer

Head of the Department of Dermatology

Hôpital Necker – Enfants Malades

President of the Genodermatoses & Rare Skin Disorders Network Scientific Committee of the Fondation René Touraine







### What is an ERN?







### «Imagine ...

• if the hest specialists

• from

could

to tac



Reference

Networks

itions

a concentration of knowledge and resources»

### Legal background

- Directive 2011/24/EU on patients' rights in crossborder healthcare
- Commission delegated decision 2014/286/EU and annex listing the criteria and conditions that healthcare providers and the ERNs should fulfil
- Commission implementing decision 2014/287/ EU and annex containing criteria for establishing and evaluating ERNs, including the exchange and dissemination of information about the ERNs

### **Establishment of an ERN**

- At least 10 healthcare providers (HCP)
- From at least 8 different Member States
- Each healthcare provider must be endorsed by its respective Member State
- All Members of a Network must have in common the expertise in a certain field, or certain treatment(s) offered or in diseases or health conditions
- Each HCP must fulfill general and specific criteria defined by the EC and the ERN

### Assessment of an ERN

- To ensure that it fulfils all the criteria for Networks and its Members as provided in the Commission Delegated Decision:
  - -the network proposals are currently technically assessed
  - by an independent assessment body

### **Approval of an ERN**

- Based on the technical assessment
- The Board of Member State will decide the approval of the Networks and membership proposals (by the end of 2016-2017)
- ERNs are approved for a 5 year period

# Very restrictive conditions for application

 One application by speciality/thematic network to avoid fragmention, overlapping and too limited scope of the network proposals

 Only open to expert centers from EU Member States + Iceland, Lichtenstein, Norway with a written statement from their respective national authorities certifying that their participation is in accordance with their MS national legislation

### **Key role of Patient Groups**

- To enable the full engagement of patient groups through democratic representation, support and quality contribution,
- Eurordis has organized Policy Action Groups based on the "ERN disease grouping"
- One is organized specifically on rare & complex skin disorders







### **ERN-Skin**

A long journey...



### ENODERMATOSES and rare Skin disorders NETWORK (FRT)



 Definition: the European and international network on rare genetic skin diseases for professionals <u>and patients</u>

• Date of creation: 2003

Geographical Coverage: 30 European, Mediterranean and Middle-

**Eastern countries** 

Number of partner teams: 52

• <u>Goal: to</u> improve health care and social support for genodermatoses patients by promoting a patient-based approach

 Source of funding: Fondation René Touraine, European Union, European Academy of Dermatology and Venereology, Corporate Donations, Private Donations

Since 2008, the Fondation René Touraine **Genodermatoses & Rare Skin Disorders Network** has been identified by the European Commission as a pilot project for European Reference Network for Rare Diseases


### GENODERMATOSES & RARE SKIN DISORDERS NETWORK

### A COOPERATIVE APPROACH



 The Network develops an inclusive approach to involve in the network experts and centers taking care of patients

 The Network works in close collaboration with other networks such as Geneskin and EB-Clinet as well as patient groups and alliances, Eurordis and also rare diseases structure as Orphanet, and EADV Task forces



RARE AND UNDIAGNOSED SKIN DISORDERS



# ERN-Skin Partners



Inclusive approach: letter to the 51 representatives in the Board of Member States on European Reference Networks to identify teams willing to join the proposal for an ERN-skin and complex or unexplained skin disorders

Health care providers had to fulfill general and specific criteria defined by the EC and the ERN HCP had to be endorsed by its own Member state

### **ERN-SKIN**


56 EXPERT CENTRES FROM 18 COUNTRIES

**INCLUDING 30** 

**EXPERT CENTERS** 

FOR EB PATIENTS

IN 17 COUNTRIES Ireland



# The network application and all partners passed the first eligibility check (August 2016)

(after evaluation by the the Board of Member State checking all the documents)

## Many expert centers could not join for administrative issues

 In some member states, national rules were not yet in place to endorse expert centers

 The call was not open to non EU countries such as Switzerland

# Cooperation with these expert centers

- Expert Centers in non EU Member States:
  - Participation to the ERN-activities
  - Sharing information

- Expert Centers in EU Member States + EEA countries can join an approved ERN anytime over the 5 years if they
  - are endorsed by their national authorities
  - fulfill criteria defined by the EC and the ERN-Skin







# ERN-Skin OBJECTIVES ORGANISATION EXPECTED OUTCOMES





# ERN-SKIN Sub Thematic groups DISEASES APPROACH

 The aim is to cover all rare, complex and undiagnosed skin diseases in children and adults requiring a highly specialized healthcare and multidisciplinary approach

 Inclusive and stepwise approach based on existing and mature networks and taskforces

Multi-year disease expansion plan

### 12 SUB THEMATIC GROUPS

Epidermolysis
Bullosa
eb Clinet

Ichthyosis & Palmoplantar Keratoderma

Dysplasia
including Skin
Fragility Disorders &
X-linked cutaneous
disorders

Monogenic
Connective Tissue
Disorders

Cutaneous Mosaic Disorders

Nevi & Nevoid Skin
Disorders & Complex
Vascular Malformations
& Vascular Tumours

Cutaneous diseases related to DNA Repair Disorders Autoimmune bullous diseases and severe cutaneous drug reactions

Hidradenitis suppurativa PAPA, PAPASH, PASH, PASS, SAPHO, Behcet, Degos

Photosensitivity

Non bullous complex autoimmune/ inflammatory cutaneous diseases

Premature Skin Ageing Rare cutaneous proliferation in children and adults

Subthematic groups to be included in the ERN-Skin expansion plan

### ERN-SKIN: Sub thematic groups The Rational

- -Misdiagnosis (poor skin knowledge among HCP)
- -Ignorance regarding the management of skin symptoms inflammation, skin barrier alteration, malnutrition, sepsis, pain
- -Lack of training of paramedical teams for the management of a severe involvement o the skin
- -Poor recognition of the skin alteration as a handicap
- -Poor social integration of patients
- -Life-threatening diseases, skin carcinogenesis due to inflammation (chronic wounds...), immunosuppression or genetic predisposition, secondary effect of therapeutic attempts
- -The cost of treatments

### ERN-SKIN: Sub thematic groups The Rational

- -The complex pathophysiologic mechanisms of the different sub thematic groups often match each other: the better understanding of some skin diseases will be a key to have a better understanding of the others, providing a better knowledge on the skin biology
- (example: collagen VII anomalies in hereditary EB/collagen VII autoantibodies in acquired EB)
- -Each sub thematic group needs a multidisciplinary approach objective to develop a collaborative approach with other ERNs

## **Sub Thematic groups DISEASES APPROACH**

### HIGH-LEVEL PATIENT MANAGEMENT

- Diagnosis
- Treatment
- Follow-up
- Management
- Best practice
- Multidisciplinary advice
- Clinical guidelines
- Cross-border patient pathways
- Empower patients

Each sub
Thematic
group is led
by a leader
team

2 coordinators

Specific road map Specific outcomes Specific criteria

#### RESEARCH

- Identify and fill research gaps
- Develop collaborative research
- Epidemiological surveillance
- Share Registries
- •Rare skin diseases burden
- Deep phenotyping

### Epidermolysis Bullosa ebc



### HIGH-LEVEL PATIENT MANAGEMENT

Coordinators: M. Jonkman (NL), J. Mellerio (UK)

Core Group: A. Diem (AT), C. Bodemer (FR), D. Kiritsi (DE), M. El-Hachem (IT), R. de Lucas (ES)

#### RESEARCH

Coordinators: L. Bruckner-Tuderman (DE), I. Leigh (UK), G. Zambruno (IT)

#### Core Group:

M. Pasmooji (NL), D. Castiglia (IT), A. Nystroem (DE), M. J. Escamez Tolarado (ES), B. Mayer (HU), E. O'Toole (UK)

#### **Patient Representatives**


M. Jaega (Debra UK), A. Kennan (Debra Ireland), E. Makow (Debra Spain),

C. Robinson (Debra International)

#### TRANSVERSAL GROUPS

for a transversal and complementary approach

### **Create synergy**



### Expected Clinical Outcomes defined with patient representatives

- Easy access to an expert center
- Regular training of the multidisciplinary teams
- Specific therapeutic education programs for adult, adolescent, paediatric patients
- European and national specific guidelines
- Harmonization of treatment procedure between all network partners
- Development of an individual burden score with cross-cultural adaptation
- Improvement of the patient centered care in the affiliated center
- Better visibility of the expert network in each country
- Stimulation of clinical research leading to concrete Better recognition of rare diseases by authorities
- European registries

### **ERN IT Platform**

The EC is developing an ERN IT platform to support networks in the diagnosis and treatment of rare or low-prevalence complex diseases or conditions across national borders in the European Union

#### **GENERAL COORDINATION**

1 coordinator assisted by 3 co-coordinators & project manager

PATIENT
REPRESENTATIVE
COUNCIL
(PRC)

DEEP PHENOTYPING

RE

**GISTRIES** 

e-HEALTH

PRC

#### **EXECUTIVE COMMITTEE**

2 coordinators of each dsub thematic group 1 coordinator of each transversal group



**Epidermolysis Bullosa** 

Ichthyosis & Palmoplantar Keratoderma

Ectodermal Dysplasia including Skin Fragility
Disorders & X-linked cutaneous disorders & Hair
diseases & and unclassified disorders

Monogenic Connective Tissue Disorders

**Cutaneous Mosaic Disorders** 

Nevi & Nevoid Skin Disorders and Complex Vascular Malformations and vascular Tumours

Cutaneous diseases related to DNA Repair Disorders

Autoimmune bullous diseases and severe cutaneous drug reactions

Hidradenitis suppurativa PAPA, PAPASH, PASH, PASS, SAPHO, Bechet, Degos

Photosensitivity

Non bullous complex auto immune/ inflammatory cutaneous diseases

Premature Skin Ageing Rare cutaneous tumours in children and adults

Subthematic groups to be included in the ERN-Skin expansion plan

Each group is coordinated by medical specialists and patient representative(s)

responsible for developing high level patient management and research activities

PRC

#### **ERN Board**

1 representative of each health care provider endorsed by its Member State

# Official endorsement of the ERN-Skin







### ERN tentative timeline & milestones



March - June 2016 July-October 2016

October -November 2016







Call for Networks

**Assessment** proposals

Approval ERN by Board MS

November 2016
- March 2017

Grant evaluation



March 2017



3rd ERN Conference & Kickoff meeting ERNs



